JP2007525203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525203A5 JP2007525203A5 JP2006523887A JP2006523887A JP2007525203A5 JP 2007525203 A5 JP2007525203 A5 JP 2007525203A5 JP 2006523887 A JP2006523887 A JP 2006523887A JP 2006523887 A JP2006523887 A JP 2006523887A JP 2007525203 A5 JP2007525203 A5 JP 2007525203A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- epha4
- overexpressed
- nucleic acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108010055179 EphA4 Receptor Proteins 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000021727 EphA4 Receptor Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54833504P | 2004-02-27 | 2004-02-27 | |
| US55580904P | 2004-03-24 | 2004-03-24 | |
| PCT/JP2005/003081 WO2005083086A2 (en) | 2004-02-27 | 2005-02-18 | Epha4 as therapeutic target of prc and pdaca |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007525203A JP2007525203A (ja) | 2007-09-06 |
| JP2007525203A5 true JP2007525203A5 (enExample) | 2008-02-14 |
Family
ID=34915619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523887A Withdrawn JP2007525203A (ja) | 2004-02-27 | 2005-02-18 | ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070253954A1 (enExample) |
| EP (1) | EP1730279A2 (enExample) |
| JP (1) | JP2007525203A (enExample) |
| TW (1) | TW200538739A (enExample) |
| WO (1) | WO2005083086A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2004228A1 (en) | 2006-02-28 | 2008-12-24 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-epha4 antibodies |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2166110B1 (en) * | 2007-06-08 | 2012-02-22 | Eisai R&D Management Co., Ltd. | Screening method utilizing novel substrate epha4 for gamma-secretase |
| WO2009064006A1 (ja) | 2007-11-15 | 2009-05-22 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| JP6059017B2 (ja) | 2010-12-17 | 2017-01-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法 |
| WO2012147798A1 (ja) | 2011-04-25 | 2012-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| AU2016345063B2 (en) | 2015-10-27 | 2021-08-05 | The Council Of The Queensland Institute Of Medical Research | A method of treatment and agents useful for same |
| JP7320840B2 (ja) | 2017-09-11 | 2023-08-04 | 国立大学法人北海道大学 | 癌治療薬 |
| WO2021002312A1 (ja) | 2019-07-01 | 2021-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ＥｐｈＡ４抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028184A (en) * | 1996-12-31 | 2000-02-22 | Max-Plank-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Pax6 and Pax4 nucleic acid mixtures |
| WO1995028484A1 (en) * | 1994-04-15 | 1995-10-26 | Amgen Inc. | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
| US6506607B1 (en) * | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
| AU3316600A (en) * | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| AU2002215345A1 (en) * | 2000-10-13 | 2002-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| WO2003009814A2 (en) * | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| JP4679149B2 (ja) * | 2002-09-30 | 2011-04-27 | オンコセラピー・サイエンス株式会社 | ヒト膵癌に関連する遺伝子およびポリペプチド |
| US20050260639A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
-
2005
- 2005-02-18 TW TW094104771A patent/TW200538739A/zh unknown
- 2005-02-18 WO PCT/JP2005/003081 patent/WO2005083086A2/en not_active Ceased
- 2005-02-18 EP EP05710681A patent/EP1730279A2/en not_active Withdrawn
- 2005-02-18 US US10/590,801 patent/US20070253954A1/en not_active Abandoned
- 2005-02-18 JP JP2006523887A patent/JP2007525203A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilkins et al. | Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth | |
| Zhao et al. | A folding-based electrochemical aptasensor for detection of vascular endothelial growth factor in human whole blood | |
| Lagarou et al. | dKDM2 couples histone H2A ubiquitylation to histone H3 demethylation during Polycomb group silencing | |
| Berdeaux et al. | SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes | |
| Hirner et al. | MuRF1-dependent regulation of systemic carbohydrate metabolism as revealed from transgenic mouse studies | |
| Iyer et al. | Dynamic nuclear and cytoplasmic glycosylation: enzymes of O-GlcNAc cycling | |
| Friederich et al. | Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder | |
| Van Damme et al. | N‐terminal acetylome analysis reveals the specificity of Naa50 (Nat5) and suggests a kinetic competition between N‐terminal acetyltransferases and methionine aminopeptidases | |
| Chang et al. | Role of myosin light chain phosphatase in cardiac physiology and pathophysiology | |
| Ni et al. | Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells | |
| Tsika et al. | Overexpression of TEAD-1 in transgenic mouse striated muscles produces a slower skeletal muscle contractile phenotype | |
| CA2403817A1 (en) | Methods of modulating hair growth | |
| JP2006500948A5 (enExample) | ||
| Lu et al. | Distributive O-GlcNAcylation on the highly repetitive C-terminal domain of RNA polymerase II | |
| McAllister et al. | Mass spectrometry based method to increase throughput for kinome analyses using ATP probes | |
| JP2007525203A5 (enExample) | ||
| Ge et al. | Nucleation and propagation of heterochromatin by the histone methyltransferase PRC2: geometric constraints and impact of the regulatory subunit JARID2 | |
| US20050014264A1 (en) | Method of introducing siRNA into adipocytes | |
| Nicolet et al. | Sequence determinants as key regulators in gene expression of T cells | |
| Lossie et al. | Molecular mechanism regulating myosin and cardiac functions by ELC | |
| Williams et al. | Long tracts of guanines drive aggregation of RNA G-quadruplexes in the presence of spermine | |
| Westfall et al. | Role of troponin I phosphorylation in protein kinase C-mediated enhanced contractile performance of rat myocytes | |
| KR20210030342A (ko) | Bag3 유전자 요법 최적화 | |
| Westfall et al. | Functional analysis of troponin I regulatory domains in the intact myofilament of adult single cardiac myocytes | |
| Pergande et al. | Mass spectrometry-based multiomics identifies metabolic signatures of sarcopenia in rhesus monkey skeletal muscle |